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Abstract
SOLUBLE OLIGOMERIC ABETA42 AFFECTS
MICROGLIA ACTIVATION AND MITOCHONDRIAL
RESPIRATION
Cong Tan

Microglia activation is associated with many neurodegenerative diseases such as
Alzheimer’s disease (AD). When activated, microglia cells change their morphology and become
phagocytic. In the Alzheimer’s brain, microglia cells play an important role in scavenging plaquedamaged cells and in clearing Aβ plagues. Soluble oligomeric Aβ (oAβ) is capable to stimulate
microglia activation. In AD brain, microglia cells accumulate around senile plaques as a hallmark of
the pathology. Recently, we found that mitochondrial oxidative phosphorylation is affected in a
dose-dependent manner in a microglia cell line (C8-B4) and primary rat glia cell. Mitochondrial
basal, maximal and spare respiration capacities increase at low concentrations of oAβ and then
decline at higher concentrations. Flow cytometry for markers of microglial activation (IBA1
upregulation) similarly shows a low dose increase and a high dose decline. In contrast, the oAβ
stimulation does not alter the mitochondrial oxidative phosphorylation in a mouse hippocampal
neuronal cell line (HT-22), suggesting a brain cell-specific response to oAβ.Our experiment results
suggest that at low concentrations of oAβ, which would normally occur in healthy brains, an
increased mitochondrial respiration hints that microglia activation responds to mild oAβ stimulation.
In contract, at higher pathological levels of oAβ, microglial activation and its associated
mitochondrial functions are inhibited which may prevent phagocytosis and allow the accumulation of
Aβ.
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CHAPTER 1: INTRODUCTION

1.1 Brain
Brain, the most complex organ, only weighs 2% of total body weight of
human but consumes 20% of total energy. It takes control of the other part of body
by processing enormous amount of information generated from brain and other
organs (Raichle & Gusnard, 2002) (Raichle & Gusnard, 2002). Unlike other cells,
neurons do not undergo cell division. Due to the nature of the neurons and the
heavy load of information, brain has its unique vasculature to protect all of the
vulnerable nervous tissue. In the brain, a blood-brain barrier (BBB) is formed by
brain endothelial cells to selective permeable to certain molecules (e.g. water,
glucose, amino acid) separate the peripheral blood from brain. Blood–brain barrier
is a natural protection barrier to protect central nervous system (CNS), including
brain and spinal cord, effectively from many infections (Giudetti, Romano,
Lavecchia, & Gaetani, 2015). Thus the infections are rare in the CNS, and also
hard to treat if there is one due to the delivery difficulty usually also exists for the
treating drugs (e.g. antibiotics). Although the blood–brain barrier becomes more
permeable during inflammation, the antibiotics and phagocytes still have a hard
time passing the BBB.
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1.2 Microglia
1.2.1 Definition
Microglial cells are a type of brain glial cell that function very similarly to
peripheral macrophages. They compose only 10-20% of brain cell population, but
play an important role in “immune privileged” central nervous system. Microglia cell
has very active processes, and through microglia the brain has a capacity for an
active innate immune response (ElAli & Rivest, 2015). Microglia cell can play
versatile function under different conditions. Microglia helps with neural
development as well as adult neurogenesis. They facilitate synaptic interaction:
including

surveilling

surrounding

environment,

pruning

synaptic

neurons,

phagocytizing damaged cells and plaques, mediating dynamic synaptic plasticity.

1.2.2 Function
Microglia cells are sensitive to their microenvironment. Their primary roles
are the maintenance of normal CNS functions (Elkabes, DiCicco-Bloom, & Black,
1996; Sierra et al., 2010; Tremblay et al., 2011; Wake, Moorhouse, Jinno,
Kohsaka, & Nabekura, 2009). Under normal conditions, they are thought to be in
a resting state, keep surveying surrounding area using their highly dynamic and
plastic ramified processes before get activated upon environmental alterations
and homeostasis change (Kettenmann, Hanisch, Noda, & Verkhratsky, 2011;
Nimmerjahn,

Kirchhoff,

&

Helmchen,

2005).

Microglia

cells

constantly

communicate with neighbor astrocytes and neurons, and transmit neurotrophic or
2

neurotoxic factors as well as inflammatory mediators. Under pathological
conditions, microglial functions are largely dependent on their activation stimuli;
whereas moderate CNS damage evokes protection by microglia (Kettenmann et
al., 2011), intensive acute activation (for example in spinal cord injury, optic
nerve

crush,

or

stroke)

and

chronic

activation,

which

characterizes

neurodegenerative diseases, render these cells neurotoxic, potentially impairing
neuronal activity (Hanisch & Kettenmann, 2007; Perry, Nicoll, & Holmes, 2010;
Scheffel et al., 2012) Such a phenotype not only prohibits microglia from
resolving inflammatory damage but rather contributes to the vicious cycle of
toxicity and calls for additional assistance to terminate the local inflammation.
Microglia can transform between different morphological phenotypes under
different stimuli, and play different roles under different activation status(Morris,
Clark, Zinn, & Vissel, 2013) Based on typical functional categories, it is usually
differentiated into: ramified surveillance resting state, classical/pro-inflammatory
(M1) state and alternative/Anti-inflammatory (M2) state.

1.2.3 Phenotype
Altered microglial function can trigger pathological conditions including
cognitive disorders (Dibaj et al., 2012). Microglia activation is profound in CNS
pathological conditions, especially AD in which it is believed to be one of the
contribution factors in the disease progression.
3

Inflammatory processes are believed to play an important role in a number of
neurodegenerative diseases including Alzheimer’s disease, Parkinson’s disease,
Prion disease, multiple sclerosis etc (Dheen, Kaur, & Ling, 2007). The
inflammatory response is mediated by the activated microglia, which responds to
inflammatory stimuli such as neuronal damage and infection. However it remains
unclear whether microglial cells activation is beneficial or detrimental in
neuropathological conditions. Figure 1.1 shows the proposed relationship of
microglia phenotypical activation states with different functionality. Under normal
conditions, microglia exists in a resting state with ramified morphology. Upon
different immunological stimuli they polarize into M1 or M2 phenotype. The M1
dominant polarization contributes to extensive microglia-mediated neurotoxicity,
increased pro-inflammatory cytokine release and aggravates neurodegeneration.
The M2 dominant polarization contributes to tissue repair, resolution of
inflammation, phagocytosis and angiogenesis.

4

Fig 1.1 - State of Microglia and phenotypical change. Microglial cells maintain resting state under normal
physiological conditions (grey), and upon stimuli polarize to classical/pro-inflammatory M1 (orange) and
alternative/anti-inflammatory M2 (blue) states. When M1and M2 states are balanced in the system with
neuron (green), the overall functions of microglia are balanced (middle panel). But when M1 state possessed
dominant position, altogether microglia cells contribute to neuron degeneration, accelerated aging, and increase
pro-inflammatory cytokine release (bottom left). When M2 state overweigh M1 state, microglia cells tend to
resolve inflammation, repair damaged tissue, help homeostasis by phagocytosis and promote angiogenesis to
bring more nutrition and oxygen to facilitate local tissue healing.
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1.3 Alzheimer’s disease
1.3.1 Definition and pathology
Alzheimer’s disease (AD) is a chronic neurodegenerative disease and is the
6th leading cause of death in the United State (ALZ org website). AD clinically
characterized by progressive cognitive decline and impaired function of daily
activities (McKhann et al., 1984). The pathology of AD is the production and
deposition of the β-Amyloid peptide (Aβ) extracellularly, and accumulation
neurofibrillary tangles of phosphorylated protein tau. Aβ peptides are formed by
cleavage at certain positions of the amyloid precursor protein (APP) and results in
different length Aβ peptides. Aβ peptides aggregate to form multiple flexible
soluble oligomers and insoluble fibril. It is believed that oligomeric Aβs, especially
the 1-42 peptide form is the most toxic and may be the causative agents in AD.
Aβ can cause toxicity to neurons directly and also cause neuronal damage
by activating surrounding microglia cells (Yankner, Duffy, & Kirschner, 1990).
Recent findings show that the most potent form of oligomeric amyloid-β (oAβ42)
has been shown to rapidly activate microglia through multiple pathways at uM
concentration (Franciosi, Choi, Kim, & McLarnon, 2005; Koenigsknecht &
Landreth, 2004). This activation is triggered by formyl peptide receptor-like
1(FPRL1) (PMID: 11316806) or uptaken by raft aggregation (Persaud-Sawin,
Banach, & Harry, 2009), P2Y2 receptor (H. J. Kim et al., 2012) and cause an
inflammatory cascade, accompanied by a nuclear factor kappa-B (NFkB)6

dependent signaling pathway. In the AD Patients’ brains, the SR-A1 (Block, Zecca,
& Hong, 2007; El Khoury, Hickman, Thomas, Loike, & Silverstein, 1998) of
microglia is upregulated, which is also demonstrated for scavenger receptors upon
injury and cytokines stimulation.
Energy deficiency also contributes to AD. Recent research (Yao et al.,
2009) shown that mitochondrial bioenergetic deficit precedes Alzheimer's
pathology in female mouse model of Alzheimer's disease. The research on the
relationship of glucose transport and utilization (Gimeno-Bayon, Lopez-Lopez,
Rodriguez, & Mahy, 2014) shown that microglia activation phenotype are closely
relate to the adaptation pathway of energy production. All together suggest
malfunction of mitochondrial energy production may compose an important factor
in the contribution of microglia mediated neurodegeneration.

1.3.2 AD and microglia
Microglia activation is closely associated with Alzheimer’s disease, and in
its over-activated state, contributes to neurotoxicity neuronal death. In AD brain,
microglia accumulation around senile Aβ plaques (McGeer, Itagaki, Tago, &
McGeer, 1987) suggests microglia may play an important role in clearing Aβ
plagues and in scavenging Aβ plaque damaged neurons. Fig 1.2 shows microglia
accumulation around Aβ plaque in the brain of AD transgenic mouse model.
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Microglia cluster around Aß plaques
Microglia (Iba-1, brown), Aß plaque (4G8, red)

Fig 1.2 Microglia (stained in brown by anti-IBA-1) accumulate around Aβ plaque (stained in Red by
4G8) in transgenic mouse models of Alzheimer’s disease. Frank Heppner, Institute of Neuropathology,
Charité – Universitätsmedizin Berlin

Although microglia activation is not considered as a specific pathological
hallmark of AD, the phenomenon is found in AD brain, even years before
symptoms become clinically apparent. Fig 1.3 shows a positron emission
tomography (PET) imaging of microglia activation in healthy brain and AD patient
brain.
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PET imaging of microglia in neurodegeneration
65 years old, disease duration of 5
years

74 years old

11

Fig 1.3 The uptake of the [ C]-PK11195 ligand to the peripheral benzodiazepine receptor, which is
overexpressed in activated microglia, is shown according to color scale. Nature Reviews Neuroscience 8, 57–
69 (Block et al., 2007)
Microglial activation can be quantified in vivo using PET imaging and [11C]PK11195

(1-(2-chlorophenyl)-N-methyl-N-1(1-methylpropyl)-3-

isoquinolinecarboxamide). [11C]PK11195 is a highly specific ligand for the
peripheral benzodiazepine-binding site (PBR), also called the translocator
protein is

expressed

by

cells

of

the mononuclear macrophage

lineage

(Papadopoulos, Lecanu, Brown, Han, & Yao, 2006), and is markedly increased in
activated microglia. Using [11C]PK11195 and PET, microglial activation has already
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been demonstrated in several neurodegenerative diseases (Venneti, Lopresti, &
Wiley, 2006) including AD.
Upon activation, microglia mediated inflammatory responses, but their
functions remain controversial (Dheen et al., 2007). Chronic activation is believed
to be cytotoxic to neurons by releasing pro-inflammatory cytokines and reactive
oxygen species (ROS), proteinases and complement proteins. On the other side,
alternative microglia activation, usually anti-inflammatory, is necessary in
maintaining homeostasis, repair and recovery.
Many researchers, using different in vivo and in vitro models, have shown
that soluble oligomers of Aβ activate microglia and induce microglia-mediated
neurotoxicity and neuron degeneration (Maezawa, Zimin, Wulff, & Jin, 2011;
Mattson, 2004), thus suppression of microglia activation has been proposed as a
potential and effective therapy to treat neurodegenerative disease. But the
functions of microglia at low dose Aβ or in early stage AD development still remain
unclear. It is unknown if microglial cells are detrimental at the very beginning of AD
and how microglia activation phenotypes may influence AD progression.

1.3.3 Hypothesized microglial activation, neuronal death and the therapeutic
relevance.
In term of further understanding the microglia’s role in AD, Block et al. has
hypothesized a possible correlation of the progression of Alzheimer’s disease with
the time line of microglial activation(Block et al., 2007). They postulate that after an
10

initial unknown instigating stimulus, neuron became damaged; causing microglial
activation that will be driven by the further loss of neurons throughout the disease.
Fig 1.4 shows a possible microglial activation correlation with neuronal death and
the therapeutic relevance.

Fig 1.4 Microglial activation, neuronal death and the therapeutic relevance. Nature Reviews
Neuroscience 8, 57-69 (Block et al., 2007)
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Although the reasons of initial stimuli may be different and as well as the
progression rate of neuron loss for each patient, microglial activation can change
their beneficial role into a deleterious one after the disease pass a threshold of
beneficial window. Microglia activation (reactive microgliosis) then may cause
further neuronal loss and resulting in a negative feedback of neurotoxicity and
worsen neurodegenerative disease.
The current problems with the disease are not only lacking the functional
treatment to reverse the pathology but also late diagnosis outside the optimal
therapeutic window long after extensive damage has occurred. Lack of knowledge
of the microglia’s clear role in the disease progression and neuronal damage, and
the diagnosis methods holds back possible therapeutic application. If a clear
threshold of microglia activation could be determined, then anti-inflammatory
therapy could be applied to reduce microglial activation to non-deleterious levels
using early detection of microglial activation through, for example, in vivo imaging.
This promising approach can delay, reduce the progression of AD before
irreversible damage occurs.

1.4 Energy utilization in the brain
1.4.1 Glucose utilization
The brain has a very high energy consumption demands considering its
size. The main energy expenditure is consumed to maintain acting potential
generated by nerve cell, as well as axonal and dendritic neuron transmitter
12

transport and tissue repair. Although brain can utilize other metabolites in special
cases, glucose is the most important fuel for energy generation. Glucose cross the
BBB by facilitated diffusion, and is taken up by brain cells via mediated by glucose
transporters.
In the cell, glucose is phosphorylated to glucose-6-phosphate that is
metabolized further into pyruvate, which is also called glycolytic pathway. Glucose6-phosphate can be also utilized as substrate for the pentose phosphate shunt and
converted into glycogen. A fraction of pyruvate can be transported into brain
mitochondria and devoted to the oxidative phosphorylation and metabolized in the
Krebs cycle. The other fraction of pyruvate in the cytosol is converted to lactate by
lactate dehydrogenase. The exact fraction of the proportion is not known in vivo,
and I assume the fraction is flexible due to the condition and environment,
especially the energy and other molecular needs.

1.4.2 Glycolysis
Glycolysis is the metabolic pathway that converts glucose into pyruvate,
which is an oxygen-independent metabolic reaction (shown in Fig 1.5). The end
products are used to convert carbohydrates into fatty acids and cholesterol. It
utilize the NADH as the reaction substrate by oxidizing NADH and transferring two
electrons to pyruvate converted into lactate.

13

Glucose
Hexokin

ase
Glucose-6-Phosphate

2 ADP
2 ATP
Pyruvate

Lactate

Acetyl-CoA

Fig 1.5 Glycolysis and Post-glycolysis process flow chart. Glycolysis is the metabolic pathway that converts
glucose C6H12O6 into pyruvate via a series of intermediate metabolites. The end product pyruvate then
converted into Lactate by anoxic regeneration or Acetyl-CoA (in mitochondrion) to further synthesize fatty
acid and cholesterol.
1.4.3 Mitochondria respiration
Mitochondria act as the main powerhouse of the in most eukaryotic cells.
Most of the reactions of energy generation are happened in the mitochondria. This
ATP production organelle is composed of a double membrane structure; with most
of the task completing proteins resides on the inner membrane. The major protein
14

forms in electron transport chain (ETC) comprises enzymatic electron donors and
acceptors proteins, including NADH dehydrogenase (Complex I, oxidizing the
NADH produced from the Krebs cycle), succinate dehydrogenase (Complex II),
cytochrome c reductase (Complex III) and cytochrome c oxidase (Complex IV).
Each electron donor protein passes electrons to an electron acceptor, which
further donates these electrons to downstream acceptor until pass the electrons to
terminal electron acceptor—oxygen. All together, they transfer electrons from
NADH and succinate pass through the ETC to oxygen further reduced to water
and pump protons (H+) into the intermembrane space to generate a proton
gradient across the inner membrane. The electron transportation releases energy,
and ADP is phosphorylated to ATP in the process using the energy thus this
process is called oxidative phosphorylation. Fig 1.6 illustrates the structure of the
mitochondria and the ETC as well as the substrate of each complex.
A small percentage of electrons may not undergo oxidative phosphorylation
but directly leak to oxygen, forming a highly reactive molecule –free-radical
superoxide. Superoxide is one of the major contributors of oxidative stress; it has
been implicated in many diseases.
As the proton accumulated to certain concentration enough in the
intermembrane space, the electrochemical gradient is established to lead protons
back to the matrix through the ATP synthase complex and synthesize ATP.
Besides supplying cellular energy, mitochondria influence other cellular functions,
such as cell signaling, cellular differentiation, and apoptosis, as well as maintaining
control of the cell growth. Mitochondria malfunction have been shown to be
15

correlated

closely

with

several

diseases,

including mitochondrial

disorders, cardiac dysfunction, heart failure and autism.

Fig 1.6 Mitochondria and electron transport chain. The electrons pass through ETC and provide the proton
gradient to facilitate ATP synthesis. https://en.wikipedia.org/wiki/Electron_transport_chain

1.5 Overall connection and novelty
Mitochondrial dysfunction has been studied intensively as it lead to
neuronal cell survival or death, not only because they regulates energy
metabolism but also mediate cellular death pathways. The byproduct of energy
generation through mitochondrial oxidative phosphorylation—reactive oxygen
species (ROS) contribute to oxidative stress and cause damage serve as one of
the most important pathogenesis of Alzheimer's disease. Many studies focus in the
16

mitochondria functions in neuronal cells, since neurons are highest energy
demanding cells in the brain. Other researchers studied the microglia contribution
in the Alzheimer’s disease progression. But the energy genesis as well as
mitochondria function in cell cycle in the microglia under different states in
Alzheimer’s brains and its relationship towards interaction with surrounding
neurons, astrocytes and endothelial cells are not clear.
It has been shown that fibrillary forms of amyloid-beta could induce
microglia activation and inflammatory responds in microglia cell line BV-2 and
primary microglia cells through Toll like Receptors and integrin. Some researchers
believed that resting microglia react to fibrillary form of Aβ but do not detect
oligomers or oligomer-induced neuronal damage. But giving the fact that the
soluble oligomeric form of Aβ is the most cytotoxic form of Aβ, it raised the
question: do microglia react with soluble oligomeric Aβ in a manner that help
maintain the homeostasis in the early stage before Aβ plaque forms and doing a
beneficial job?
In most related experiment involved Aβ, the dose ranges from uM to
hundreds of uM in vitro were used. But according to post mortem samples from AD
patients brain, the average Aβ concentration is at 15pM compared to less than
5pM in the control group (Perez-Nievas et al., 2013).

To better mimic the

pathological condition, in this project much lower doses were used to serve in the
in vitro model that avoids any high concentration off–target effect.
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CHAPTER

2:

MITOCHONDRIAL

OLIGOMERIC
RESPIRATION

ABETA
CHANGE

IN

INDUCED
MICROGLIA

CELLS

2.1 Introduction
Microglia could help restore the homeostasis, heal and rescue tissue
damage or mediate inflammatory responses upon activation. Their functions
remain controversial and are a balance of beneficial and detrimental (Dheen et al.,
2007). The chronic activation is believed to be cytotoxic to neurons by releasing
pro-inflammatory cytokines and reactive oxygen species (ROS), proteinases and
complement proteins. On the other hand, alternative microglia activation, usually
anti-inflammatory, is necessary in maintaining homeostasis, repair and recovery.
Many researchers using different in vivo and in vitro model, have shown
that soluble oligomers of Aβ activate microglia and induce microglia-mediated
neurotoxicity (Maezawa et al., 2011; Mattson, 2004), thus suppression of microglia
activation especially microglia-mediated inflammation or elimination of microglia
has been designed as a potential and effective therapy to treat neurodegenerative
disease.
But the functions of microglia at low dose Aβ or in early stage AD
development still remain unclear. Questions of whether microglia starts to be
detrimental at very beginning and how microglia activation phenotypes may
influence AD development remain.
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Recently, we found that mitochondrial oxidative phosphorylation is affected
in a dose-dependent manner by oAβ42 treatment in a microglia cell line (C8-B4).
Basal, maximal and spare respiration capacities of mitochondria increase at low
pico-molar concentrations of oAβ42 and then decrease at higher concentrations. In
contrast, the oAβ42 stimulation does not alter the mitochondrial oxidative
phosphorylation in a mouse hippocampal neuronal cell line (HT-22), suggesting a
brain cell-specific response to oAβ42.
Microglia possessed two different potential activation pathways, Classical
M1 pro-inflammatory and Alternative M2 anti-inflammatory pathways. Due to two
routes of activation and the different roles in inflammatory response, we
hypothesize that 1) Low dose oAβ42 increases mitochondrial oxidativephosphorylation due to the high energy demanding cell activities (Gimeno-Bayon
et al., 2014), and this effect vanished at higher dose. 2) The oAβ42 induced
mitochondria functional changes are specific in microglia cell types.
The first project is focused on Specific Aim #1: To determine if oAβ42
influence mitochondrial oxidative-phosphorylation differently at low dose vs
high dose in various cell types.
Hypothesis: Low dose pM oAβ42 increase mitochondrial respiration which
is high efficacy energy generation while high dose Aβ42O dampens this effect.
Rationale: Studies using postmortem brains as well as transgenic mouse
models of AD (Gimeno-Bayon et al., 2014; Spuch, Ortolano, & Navarro, 2012)
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have shown that Aβ induced oxidative damage is associated with mitochondria
dysfunction during AD progression. Aβ blocks the transport of nuclear-encoded
mitochondrial proteins, disrupts electron transport chain, and increases ROS
production. But most of the researches focused on late stage of AD or using high
dose Aβ treatment to mimic the pathological environment. It make sense that Aβ
accumulate in aged brain, but what is more interesting is the response during early
stage of the disease progression, and how other cells especially microglia cells
works to maintain an optimal working condition.
EXP 1. Evaluation the mitochondrial functional changes influenced by low
dose and higher dose of oAβ42 by measuring the mitochondrial respiration
parameter in oAβ42 treated microglial and neuronal cells.
EXP 2. To evaluate the toxicity of oAβ42 at different concentrations by
measure the cell viability using Calcein-AM assay and propidium iodide (PI)
staining.
EXP 3. To further assess the energy metabolism under oAβ42 stimuli, in
some groups carry glycolysis assay to evaluate the energy compensatory
mechanism.
Expected Results and potential problems:
Low dose oAβ42 treatment may cause mitochondrial respiration changes
expected to be reflected in Mito-Stress assays. The respiration of mitochondria is
expected to be increases in order to support microglial activation. This increase is
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expected to be of small scale and persist for a long time unless the microglia
returns to a resting state and don’t need the energy support anymore. In contrast,
neuronal cells respond little to oAβ42 at low dose but may be vulnerable at high
dose due to the toxicity of oAβ42 to neurons.
Mitochondrial respiration is expected to increase in C8-B4 cells, to response
to low dose oAβ42 stimuli. It is known that oAβ42 may impair synaptic plasticity and
cognitive function in AD models, so a potential problem is to have a relative low
dose but can still cause enough effect. Another possible problem is oAβ42
characterization, due to the many forms of Aβ42, the yield of oAβ42 may not be
exactly the same after storage.

2.2 Material and Method

Cell culture
Four cell types were evaluated in this part: 1. Microglia cell line C8-B4; 2.
Neuronal cell line HT-22; 3 Primary mouse glia cells; 4. Primary mouse neurons.
They were chosen to be assessed their live cell mitochondrial function using
Extracellular Flux Analyzer.
C8-B4 (ATCC) and HT-22 (generous gift of Dr. David Schubert Salk
Institute, San Diego, CA; (Jung, Wilson, & Simpkins, 2006)) cells were grown in
Dulbecco’s modified Eagle’s medium (DMEM; Hyclone) containing 10% fetal
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bovine serum (FBS; Atlanta biologicals) and 100units/ml-100μg/ml PenicillinStreptomycin (PS; Hyclone) in 5% CO2 at 37°C.
Primary Glia cells were obtained from P2 wild type Sprague Dawley rat,
cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Hyclone)
containing 10% fetal bovine serum (FBS; Atlanta biologicals) and 100units/ml100μg/ml Penicillin-Streptomycin (PS; Hyclone) in 5 % CO2 at 37°C. At the end of
the cell culture, cells were treated with oAβ42 for 48 hours in 5 % CO2 at 37 °C.
Primary neurons were obtained from E19 embryonic wild type C57BL/6
and HAD transgenic mice carrying background of homozygous APP Swedish
genes. Cells were then cultured in neural basal media supplemented with B27 and
glutamax DIV 14 days. Cell culture media were changed twice a week 50% each
time, and cellular morphology were closely monitored under microscope. At the
end of the cell culture, cells were treated with oAβ42 for 48 hours in 5% CO2 at 37
°C.

Cells were seeded in the Seahorse 96-well plates and cultured overnight
then treated with 3.2pM, 16pM, 80pM, 400pM, 2nM, 10nM, 50nM oAβ42 for 24
hours (cell lines) or 48 hours (primary cells). The oAβ42 was prepared according to
the published method (Lambert et al., 2001; Logan, Sarkar, Zhang, & Simpkins,
2011). Synthetic Aβ42 (Lifetechnology) was dissolved in hexafluoro-2-propanol
(HFIP) and aliquot. Then HFIP was removed by evaporation overnight, store at 80°C. One aliquot was dissolved in anhydrous dimethyl sulfoxide (DMSO) to
5 mM, which was then added to ice cold DMEM without phenol red to achieve a
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concentration of 100 μM. This solution was incubated at 4 °C for 24 hours, and
then centrifuged at 14,000g for 10 min. The supernatant comprised of fibrillar-free
oligomers, as well as monomers, was used for the experiments performed in this
study. Protein concentration was determined from the supernatant and its molarity
was calculated.

Cell Viability assay
To test whether toxicity is induced during treatment which may influence the
total cell number and simultaneously impact OCR value of Seahorse assay, cell
viability using fluorescent Calcein-AM dye is also assessed under the same
treatment regimen and time.
Cell viability was assessed using Calcein-AM (calcein acetoxymethyl)
assay. Cells were washed with PBS and incubated with 1μM Calcein-AM
fluorescent probes (Life Technologies) in dark for 30min. The live cells produce
green fluorescence by active intracellular esterase which cleaves the Calcein AM
dye. Viability was measured in relative fluorescent units (RFU), and expressed as
percentage of vehicle-treated control values. To further verify the viability, the
propidium iodide (PI), which binds to nucleic acid when cell membrane was
permeable, was also applied to identify dead cells in whole population.
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Mito Stress and Glycolysis assay
The Seahorse XF96e measures mitochondrial function by analyzing the rate
of oxygen and pH change in the microenvironment surrounding the cells (as
shown in Fig 2.1).

Fig 2.1 Mitochondrial respiration parameter measurement. Light excites the embedded fluorophore then
XFe96 measures change in fluorophore emission, the measurement of Oxygen Consumption Rate
(pmoles/min) = O2 consumption ≡ mitochondrial respiration while the Extra Cellular Acidification Rate
(mpH/min)= H+ Production≡ glycolysis.

Then oxygen consumption rate (OCR) were measured before and following
1μM Oligomycin, 0.5μM Carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone
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(FCCP), 1μM/1μM Antimycin-A/Rotenone injections to examine the mitochondrial
stress parameters of oxidative phosphorylation. Five major mitochondrial stress
parameters were measured as shown above.
The extracellular acidification rate (ECAR) were measured before and
following the addition of saturating amounts of glucose (10mM), oligomycin (1uM),
2-Deoxy-D-glucose (2-DG, a competitive inhibitor of glucose) (50mM) to examine
the glycolysis, glycolytic capacity and allow calculation of glycolytic reserve and
non-glycolytic acidification.

Statistical analysis
The statistical analysis between the groups with normal distributions was
performed using Graphpad (Prism) or SPSS (statistical package for the social
sciences, IBM) software. For comparison of multiple treatments, results were
analyzed by ANOVA across group. Tukey’s test or Dunnett’s was used to adjust
for multiple comparisons in post hoc pairwise tests. The differences between
groups were considered to be statistically significant when p<0.05. Results values
are reported as mean ± standard error of means (SEM).

2.3 Results:
To test the mitochondrial function in microglia treated with oAβ, we
performed Seahorse extracellular flux assay utilizing mouse cerebellum microglia
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cell line C8-B4. The original graph and analyzed results are shown below in Fig
2.2.

C8-B4 Mito Stress parameter

24h
treatment
Fig 2.2 Mitochondrial stress parameters were measured as oxygen consumption rates (OCR). C8-B4 mouse
microglia cell line (Statistic analysis was done by One-way ANOVA and Dunnett’s post hoc analysis. *
p<0.05, ** p<0.005, *** p<0.0005) There were significant differences in most respiration parameters
treated with oAβ42 in C8-B4 cell line.
In most of the groups concentrations of oAβ as low as 3.2pM caused
mitochondrial respiration increased with a maximization at 16~80pM which are
pathological relevant concentrations of soluble amyloid-β load. This increase
rapidly diminished back to baseline at 50nM oAβ.
Since OCR is largely influenced by the cell number resides in each well. To
differentiate the effect of treatment on microglial mitochondrial respiration vs cell
number, in addition to confirming the toxicity dose of oAβ. Cell viability assay has
been applied to determine the cell number after 24h treatment. Fig 2.3 show the
cell viability measured by Calcein-AM assay which suggested that oAβ42 neither
present cytotoxicity nor induce proliferation across all dosage.
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[oAβ42]

Fig 2.3 Cell viability was measured as Mean Relative Fluorescence Units (RFU). C8-B4 mouse microglia
cell line were seeded in 96-well plate at their optimal density overnight and treated with oAβ42 for 24hours
(Statistic analysis was done by One-way ANOVA and Dunnett’s post hoc analysis. * p<0.05, **
p<0.005, *** p<0.0005) There was no significant differences in all oAβ42 treatment group in microglial
cell line.
We have been using the C8-B4 to represent the response of microglia cells.
Since cell lines are transformed cells they may adapt different energy utilization
methods other than non-transformed microglia cells in brain. We tested the effect
of oAβ at the similar dose on primary glia cells.

Primary glia cells are derived from P2 wild type Sprague Dawley rat,
cultured in vitro for two weeks and then harvested for further analysis. Fig 2.4
shown the mito stress results of 48h treatment in primary glia cells, while we also
did 24h treatment (result not shown) with less difference probably due to shorter
treatment duration.
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Primary Rat Glia Mito Stress parameter

48h treatment

Fig 2.4 Mitochondrial stress parameters were measured as OCR. Rat primary glia cells (Lower panel) were
obtained from P2 Sprague-Dawley rats and cultured for 14 days, then counted and seeded in 96-well plate
overnight and treated with oAβ42 for 48hours. (Statistical analysis was done by One-way ANOVA and
Dunnett’s post hoc analysis. * p<0.05, ** p<0.005, *** p<0.0005) There were significant differences in
most respiration parameters treated with oAβ42 in primary glia cells, and there was little change in neuronal
cell line.
To distinguish the influence of cell proliferation from the real response of
OCR to treatment, and in addition to confirm toxicity of oA, cell viability assay was
conducted to determine the cell number at the end of treatment. Results shown in
Fig 2.5 suggested that oAβ42 neither present cytotoxicity nor induce proliferation
across all dosage.
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[oAβ42]

Fig 2.5 Cell viability were measured Mean Relative Fluorescence Units (RFU). Rat primary glia cells were
obtained from P2 sprague dawley rats and cultured for 14 days, then counted and seeded in 96-well plate
overnight and treated with oAβ42 for 48hours. (Statistical analysis was done by One-way ANOVA and
Dunnett’s post hoc analysis. * p<0.05, ** p<0.005, *** p<0.0005) There was no significant differences
in all oAβ42 treatment group in primary cells, suggest oAβ42 neither present cytotoxicity nor induce
proliferation across all dosage.
Fig 2.4 show that the responses pattern of primary glia cells to oAβ
treatment showed a similar response pattern to that seen in C8-B4 cells. I
observed that to achieve more significant difference, the treatment duration in
primary glia cell (48h) is longer than C8-B4 cell line (24h) probably due to the
faster proliferation cycles of cell lines compared to primary cell. Overall the
mitochondrial stress assay and the viability assay suggests that C8-B4 cell line
represent microglia cells from murine brains very well.
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To examine the effect of oAβ on neurons at low doses, we performed same
set of experiments using three different kinds of cells: 1. Mouse hippocampal cell
line HT-22; 2. Primary neuronal cell derived from WT C57BL/6 mouse as well as
the primary and 3. Primary neuronal cell from homozygous APP Swedish mutated
mouse with C57BL/6 background.

HT-22 Mito Stress parameter

24h treatment

Fig 2.6 Mitochondrial stress parameters were measured as oxygen consumption rates (OCR). HT-22 mouse
neuronal cell line (Upper Panel) were seeded in 96-well plate at their optimal density overnight and treated
with oAβ42 for 24hours. (Statistical analysis was done by One-way ANOVA and Dunnett’s post hoc
analysis. * p<0.05, ** p<0.005, *** p<0.0005) There were significant differences in most respiration
parameters treated with oAβ42 in neuronal cell line HT-22.
In contrast of the increase induced by oAβ in both microglia cell line C8-B4
as well as rat primary microglia cells, Fig 2.6 shown that there is no significant
change induced by oAβ in neuronal cell line HT-22 cells. It suggested that the low
dose oAβ induced mitochondrial functional change is in a cell-specific manner. As
before, cell viability Calcein-AM assay was tested to ensure the effect is not
caused by the uneven number between different treatment groups. Further cell
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toxicity can be assessed by comparing the cell number in treated group with the
vehicle control group.

[oAβ42]
Fig 2.7 Cell viability was measured Mean Relative Fluorescence Units (RFU). HT-22 mouse neuronal cell
line were seeded in 96-well plate at their optimal density overnight and treated with oAβ42 for 24hours.
(Statistical analysis was done by One-way ANOVA and Dunnett’s post hoc analysis. * p<0.05, **
p<0.005, *** p<0.0005) There was no significant differences in all oAβ42 treatment group in HT-22 cell
line suggest oAβ42 neither present cytotoxicity nor induce proliferation across all dosage.

There was no cytotoxity or cell proliferation in HT-22 cells in treated groups
(shown in Fig 2.7). These suggested that the oAβ dosage we applied in these
experiments was not toxic to HT-22 cells and did not alter cell proliferation. HT-22
is an immortalized neuronal cell line, thus to verify the representability of HT-22 for
neurons, we applied oAβ treatment to two primary neuronal cells. First we tested
the primary cell derived from WT C57BL/6 mouse.
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Fig 2.8 Mitochondrial Stress parameter measured by Seahorse assay. All mito stress parameter in WT
primary neuronal cells remained same if not declined. Oneway ANOVA with Tukey’s test was applied to
analysis significant difference. * p<0.05
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Fig 2.9 Glycolysis Assay measured glycolysis parameters in WT primary neurons. All treatment groups’
glycolysis parameter didn’t seem to differ from vehicle by Oneway-ANOVA Tukey’s Post hoc analysis,
although it seems a trend of increase in glycolysis with the increase of Abeta dose.

Fig 2.8 and 2.9 shown the calculated mitostress parameter value and
glycolysis parameters respectively. Mitochondrial and glycolysis evaluations
through Seahorse extracellular flux experiments shown that there was no
significant change of OCR except a small decline at 2nM oAβ in all mitochondrial
stress parameters and there is no significantly change in all glycolysis parameters
except a tread of increase of glycolysis in a dose-dependent manner.
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Fig 2.10 Cell Viability of WT primary neurons suggest cell population doesn’t change across treatment
groups by both PI staining and Calcein-AM Assay. Data analyzed by Oneway-ANOVA Tukey’s
Post hoc analysis.

Also both PI staining for dead cells and Calcein-AM assay for live cell (Fig
2.10) to test cell viability show no difference betwwen the treated groups vs.
vehicle control.
To determine the effect of oAβ on primary neuron which carry a genetic AD
disease background, mutated with an insertion of humanized homozygous

amyloid beta precursor protein Swedish gene sequence. With the mutation,
the transgenic cell can manufacture human APP protein with the control of mouse
Thy1.2 regulatory element.

Fig 2.11 and 2.12 shown the calculated mitostress parameter value and
glycolysis parameters respectively.
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Fig 2.11 Mitochondrial stress parameter measured by Seahorse Assay. Instead of increase of mito stress
parameter in mouse primary glia, all mito stress parameter in HAD primary neuronal cells remained same
except a small decline at 50nM. Oneway ANOVA with Tukey’s test was applied to analysis significant
difference.
Seahorse extracellular flux experiments shown that there was no significant
change of OCR except a small decline at 50nM oAβ in all mitochondrial stress
parameters (Fig 2.11) and there is no significantly change in all glycolysis
parameters (Fig 2.12).
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Fig 2.12 Glycolysis Assay measured glycolysis parameters in HAD primary neurons. All treatment groups’
glycolysis parameter didn’t seem to differ from vehicle by Oneway-ANOVA Tukey’s Post hoc analysis,
although it seems a trend of increase in glycolysis with the increase of Abeta dose.

Fig 2.13 Cell Viability assay of HAD primary neurons, Cell number doesn’t change across treatment
groups in WT primary neurons by both PI staining and Calcein-AM Assay. Data analyzed by
Oneway-ANOVA Tukey’s Post hoc analysis.
We use both PI staining for dead cells and Calcein-AM assay for live cell to
test cell viability. None of them show any difference between the treated groups vs.
vehicle control group.
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2.4 Discussion
In this project we tested the effect of various concentration of oAβ (pM-nM)
in different cell types. Overall there is no effect of oAβ on all viability was observed
suggested the dosage we used in this series of experiments is not toxic to either
microglia cells or neuronal cells. In this study, our experiments using oAβ as an
insult to mimic the AD amyloid-β environment in microglia cell line C8-B4. Also by
utilizing different type of cells, we tested the specificity of the mitochondrial
response in different cell type upon oAβ stimulation. Further we examine whether
cell lines could represent non-transformed cells in term of their response pattern in
mitochondrial respiration and glycolysis assay. In all conditions, we also tested cell
viability simultaneously ensure that potential treatment effect were not the result of
changes in cell number. Our experiments results have successfully shown an
intracellular molecular response in term of oxygen consumption rate (OCR)
change upon oAβ stimuli, suggesting that microglial cell indeed respond to the
soluble form of oligomeric Aβ.
The observed changes upon low dose oAβ stimuli specifically in microglial
cells provide evidence of early involvement of microglia before Aβ plaque
formation. Thus raise the possibility that microglial function can be controlled by
regulate mitochondria function, thus the fate of beneficial or detrimental pathway of
microglia could be controlled in AD.
It is known that besides age, gender is another major risk factor of
Alzheimer’s disease. The incidence of AD is higher in women than in men. It
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cannot be simply attributed to the higher longevity of women. It has been
suspected that a specific pathogenic mechanism behind the higher incidence of
AD cases in women. One postulated hypothesis is that mitochondria from young
women are protected against amyloid-beta toxicity than males. The mitochondria
protect cells by generating less reactive oxygen species and release less
apoptogenic signals while this advantage is lost in mitochondria in aged female AD
patients (Vina & Lloret, 2010). One pitfall of these experiments is that gender
difference could not be reflected using this in vitro model although the C8-B4 cells
originally derived from female mouse, the gender effect is more systematic effect.
Another drawback is the low yield of oligomeric Aβ synthesis. Large fraction of
material Aβ converted into insoluble form during synthesis which results in the high
cost of oAβ reagent preparation. The multiple compositions of oAβ with different
number of oligomerization is also a problem, it may contribute to the variance of
groups with different concentration.
Previous studies have shown that amyloid-beta oligomer at low nanomolar
concentrations activate microglia and also induce microglial neurotoxicity (2011
JBC) in primary mice microglia cells. Researches (Perez-Nievas et al., 2013) using
post mortem samples suggested that although soluble amyloid-β did not differ
among groups between AD vs control by immunoblotting and ELISA, but
oligomeric amyloid-β load was significant higher in demented cases with
Alzheimer’s disease (15pM in AD while <5pM in Control). Thus oligomeric form is
critical among all types of amyloid-beta peptides in AD. Although there are studies
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focused on the microglia cells in AD, little is known about the mitochondrial
functions in microglia in AD. What we did in this project has fill the gap of the low
dose effect in AD in vitro model, also further explore the role that mitochondria
plays upon oAβ stimulation. The results of the cell specific response provide an
evidence of microglia function in early AD suggest that the postulate of microglia
therapy is prominent in AD treatment development.
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CHAPTER

3:

OLIGOMERIC

ABETA

ACTIVATION AND PHENOTYPICAL

INDUCED

MICROGLIA

POLARIZATION

3.1 Introduction
Based on the results of the first projects, we confirmed that microglial cells
but not neuronal cells indeed respond to very low dose of soluble oAβ specifically.
The next question is: do microglia cells change their morphology when their
mitochondrial functions get changed upon oAβ stimuli, do they undergo
phagocytosis preparation by upregulate the energy production? Or are they under
a classical activation in preparation for the released regulatory cytokines.

Another question need to be addressed in this part is to test the response of
other brain cell types upon the low dose oAβ, since little is known about the
neuronal response under such condition. In this chapter, my project is focused to
answer the question raised above and I hypothesize that: 1) Low dose oAβ42
increases microglial oxidative phosphorylation respiration and induces microglia
activation favors M2 phagocytic pathway while higher dose oAβ42 shuffled the
activation toward pro-inflammatory pathway. 2) Low and high level of oAβ42 induce
different microglia activation type which favors anti- or pro-inflammation,
respectively. 3) The favored activation phenotype is depending on the
mitochondrial respiration stimulation.
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Rationale: Due to the fast engulfment and morphology change, M2
pathway is hypothesized to be more energy demanding compared to M1, thus the
mitochondrial oxidative-phosphorylation, the main energy supply process, is
regulated accordingly. Microglia are constantly surveying surrounding environment
(Tremblay et al., 2011), prevent and slow AD by clearing Aβ. In AD brain, microglia
cells accumulate at the site of fibrillary Aβ plaques. The uptake of the most
menacing Aβ species oAβ by microglia is receptor-independent pinocytosis.

Exp. 1 Microglia phenotypical changes assessed by translocation of NFkB,
and M1 or M2 phenotypical markers expression as well as other activation marker
expression assessed by flow cytometry.
Exp. 2 Microglial morphology change assessed by confocal fluorescent
immunocytochemistry microscope imaging staining the shape of the microglial
cells. Together mitochondria localization in microglial cells upon oAβ stimuli is
assessed by mitochondrial counterstain using mitochondrial tracker (mito-red).
Exp. 3 Microglial transcriptive change during oAβ42 induced activation. In
addition to the general activation marker IBA-1, M1 activation markers (Chhor et
al., 2013; Crain, Nikodemova, & Watters, 2013) iNOS; CCL2; IL-1β and TNFα, M2
activation markers (Cherry, Olschowka, & O'Banion, 2014) Arg1; IL-10; YM1/2 and
TGF-β) (Crain et al., 2013; Michelucci, Heurtaux, Grandbarbe, Morga, &
Heuschling, 2009) were measured after 24h treatment of oAβ42, 10ng/ml LPS (M1
positive control), 1ng/ml IL-4 and IL-10 combination (M2 positive control). These
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markers were evaluated by real-time PCR. In the preliminary study, IL-10 was
upregulated in oAβ42 treated C8-B4 cells and could be a possible candidate that
increases the mitochondrial function by oAβ42.
Exp. 4 Microglia phagocytosis function was assessed by a fluorescent
microsphere assay. Cells were treated with oAβ42, LPS for 24hours, then
incubated with fluorescent dye Nile red Microsphere (d=1μm) (Life Technology).
Confocal microscopic images will be taken, and numbers of microsphere engulfed
into microglia were counted. To better quantify microsphere intake, alternatively
flow cytometry assay was used to compare a mean fluorescence intensity (MFI)
change.
Expected Results and potential problems:
Microglia phenotypical changes are expected in to be reflected in rtPCR
assays. The M2 activation is expected to be induced with oAβ42 treatment.
However, not all M2 markers increase to same extent. LPS induces typical M1
activation, and it can also regulate M2 markers. An IL-4 + IL-10 combination was
used to induce typical M2 activation. We expected no change or subtle change in
M1 activation, while M2 markers expression increase was anticipated.
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3.2 Material and Method

Cell Culture
C8-B4 (ATCC) cells were grown in Dulbecco’s modified Eagle’s medium
(DMEM; Hyclone) containing 10% fetal bovine serum (FBS; Atlanta biologicals)
and 100units/ml-100μg/ml Penicillin-Streptomycin (PS; Hyclone) in 5% CO2 at
37°C.

Immunocytochemistry Staining
We prepared rinsed coverslips well by sterile H2O (three times 5 min each)
into flat bottom 6-well plate, then allow coverslips to dry completely and sterilize
them under UV light overnight. C8-B4 cells were grown on glass coverslips
overnight, then rinsed briefly in phosphate-buffered saline (PBS). Cells were fixed
using 4% paraformaldehyde in PBS pH 7.4 for 10 min at room temperature, then
washed three times with ice cold PBS. We incubated the samples for 10 min with
PBS containing 0.25% Triton X-100 to permeablize cells, then cells were washed
in PBS three times for 5 min. Cells were incubate with 1% BSA in PBS for 1h to
block nonspecific binding of the antibodies. We then incubate cells in the diluted
primary antibody in 1% BSA in PBS in sealed container overnight at 4°C. We
washed the cells three times in PBS, 5 min each wash, then incubated cells with
the secondary antibody in 1% BSA for 1hr at room temperature in the dark. Cells
were washed three times with PBS for 5 min each in the dark, then coverslips
were mounted with a drop of mounting medium containing DAPI. Coverslips were
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sealed with nail polish to prevent drying and movement under microscope and the
slides were cured for 24hrs and stored in dark at - 20°C or +4°C.

Flow cytometry
To measure the activation phenotype, microglia were subjected to flow
cytometry analysis. After treatment with oAβ42 and LPS for 24 hours, the cultured
cells were counted and incubated with fluorophore-conjugated primary antibodies
anti-CD40, anti-CD206, anti-IBA-1. Mean fluorescent Intensities were measured
using Fortessa Flow Cytometer, and analyzed by FCS express software.

Real-time PCR
Total RNA was purified from cultured cells using the RNeasy micro kit
(Qiagen) for total RNA extractions. RNA was reverse transcribed using the
Applied-Biosystem with 2 μg total RNA sample from C8B4 microglial or primary
microglial cells. The reverse transcription reaction was performed in a total volume
of 20μL containing 2 uL 10X Reaction Buffer, 0.8 μL 25X dNTP mix, 2 μL 10X RT
random primers, 1 μL multiscribe reverse transcriptase, 1 μL Rnase inhibitor, 3.2
μL Nuclease-free water and 10μL RNA sample for 10 min at 25°C, 2 h at 37°C and
5 min at 85°C. Individual 25 μL SYBR Green real-time PCR reactions consisted of
2.5 μL of cDNA, 12.5 μL 2X SYBR Green mix (Applied Bioscience), and 5 μL of
each 12.5 μM optimized forward and reverse primers and 5 μL RNase-free water.
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Primer sequences designed are described in Table 3.1.

Target

Forward

Reverse
GTT-TCT-CCA-GCA-TTC-GCT-

IBA1

CTT-TTG-GAC-TGC-TGA-AGG-C

TC
AAG-GCC-AAA-CAC-AGC-ATA-

iNOS

CCL2

CAA-GCA-CCT-TGG-AAG-AGG-AG

CC

CAC-TCA-CCT-GCT-GCT-ACT-

GCT-TCT-TTG-GGA-CAC-CTG-

CAT-TC

CTG
AGG-ATG-GGC-TCT-TCT-TCA-

IL1-β

GCT-TCA-GGC-AGG-CAG-TAT-C

TNF-α GGT-TCT-GTC-CCT-TTC-ACT-CAC

AAG

T-GCC-TCT-TCT-GCC-AGT-TCC
CTG-AAA-GGA-GCC-CTG-TCT-

Arg1

TCA-CCT-GAG-CTT-TGA-TGT-CG

TG
TTT-TCA-CAG-GGG-AGA-AAT-

IL-10

CCA-AGC-CTT-ATC-GGA-AAT-GA

CG
CGT-CAA-AAG-ACA-GCC-ACT-

TGF-β TGC-GCT-TGC-AGA-GAT-TAA-AA

CA
CAC-GGC-ACC-TCC-TAA-ATT-

YM1/2 CAG-GGT-AAT-GAG-TGG-GTT-GG

GT

Table 3.1 shows the sequence of forward and reverse primers of target RNA
transcripts to evaluate microglial activation polarization by rtPCR assay.
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Phagocytosis assay
Microglial

phagocytosis

was

measured

by

uptake

of

fluorescent

microspheres. C8-B4 cells or primary microglia cells were cultured in DMEM
containing 10% FBS on glass coverslips overnight and treated with oAβ42, IL-4, IL10 and/or LPS. At the end of treatment, cells were incubated with Microsphere
(1μm in diameter) in PBS containing 1mg/ml BSA for additional 30min. Cells are
washed with PBS and fixed with 4% paraformaldehyde and stained with Alexa
Fluor 488 Phalloidin (Life Technology) for visualization, mounted with ProLong
Gold anti-fade reagent(Life Technology).
To better quantify the extent of phagocytosis in a given number of cells,
microglia were subjected to flow cytometry analysis. After treated with oAβ42 and
LPS for 24 hours, the cultured cells were counted and incubated with fluorescent
microsphere for 1h. Mean fluorescent Intensities were measured using Fortessa
Flow Cytometer, and analyzed by FCS express software.

Statistical analysis
The statistical analysis between the groups with normal distributions was
performed using Graphpad (Prism) or SPSS (statistical package for the social
sciences, IBM) software. For comparison of multiple treatments, results were
analyzed by ANOVA across group. Tukey’s test or Dunnett’s was used to adjust
for multiple comparisons in post hoc pairwise tests. The differences between
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groups were considered to be statistically significant when p<0.05. Results values
are reported as mean ± standard error of means (SEM).

3.3 Results
Since we observed an increase in mitochondrial respiration at low doses of
oAβ, we then assessed if C8-B4 cell are activated under these conditions. So we
carried out immunocytochemistry staining of NFkB, a transcription factor which
translocate from cytosol to nucleus upon microglial activation. C8-B4 cells were
treated with LPS 10ng/ml for 24hrs as a positive control shown in Fig 3.1.

The images of NF-kB translocation show the results of minor sign of
translocation. There is a small trend of increased translocation as oAβ treatment
concentration increases. But the translocation was not obvious enough to be
quantified using fluorescent imaging.
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a

b

c

d
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e

f
Fig 3.1 shows Immunocytochemistry images of NFkB translocation after 24h treatment of a) control, b)
3.2pM oAβ, c) 80pM oAβ, d) 2nM oAβ, e)50n oAβ and f) 4h treatment of 10ng/ml LPS. DAPI
(Blue, left panel), NFkB (Green, middle panel) and overlay right panel. Red Arron indicate the
translocation position.

Since it is hard to qualitatively and quantitatively judge the activation status
of C8-B4 cells induced by soluble oAβ, we performed a flow cytometry assay using
typical M1 (CD40) and M2 (CD206) markers of microglial activation, to determine if
oAβ induced microglia phenotypical changes.

C8-B4 cells were cultured

overnight, and then treated with oAβ42 for 24h. At the end of the treatment, cells
will be collected and incubated with primary antibodies of general activation marker
IBA-1 (Serrano-Pozo, Gomez-Isla, Growdon, Frosch, & Hyman, 2013), M1
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activation markers CD40(Hjorth et al., 2013), and M2 activation marker CD206
(Bedi, Smith, Hetz, Xue, & Cox, 2013). All activation markers expression will be
measured by the mean fluorescent intensity (MFI) change.

C8B4_Abeta LPS 24h_CD206

C8B4_Abeta LPS 24h_ CD40
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Fig 3.2 Histogram of flow cytometry assay using M1 (CD40) and M2 (CD206) marker after 24h oAβ
treatment in C8-B4 cells. X-axis is single fluorescent intensity, Y-axis is cell count.
As we can see in Fig 3.2, the oAβ treated groups did not induced M1
specific activation compared to control group, but induced M2 specific activations
slightly (peak shift right compared to control group). Both M1 marker—CD40 and
M2 marker—CD206 did not shown a significant difference between the oAβ
treated groups. LPS treatment triggered an increase in Mean Fluorescent Intensity
(peak shift to right). Interestingly LPS also induced M2 activation according to
CD206 peak shift.
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To confirm the activation indeed happened, we performed flow cytometry
assay using IBA-1 (ionized calcium-binding adapter molecule 1), a specific

Cell Count

microglial marker which up-regulated during activation process.

IBA1 (FITC)
Fig 3.3 Flow cytometry assay of IBA-1 expression. IBA-1 upregulation in higher at low dose oAβ
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treatment compare to higher dose oAβ treatment.
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As Fig 3.3 shows that IBA-1 expression was upregulated in all treatment
groups, but lower doses of oAβ (3.2pM, 80pM, 2nM) induced more shift of the
peak meaning the upregulation of IBA-1 is more compared to higher dose of oAβ
(50nM) and LPS induced upregulation.
Overall the Flow cytometry assay of IBA-1 expression in C8-B4 cell shown
that IBA-1 upregulation upon oAβ42 treatment was increased at low dose, and
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declines at higher dose. This change follows a pattern which is very similar to the
pattern of mitochondrial respiration change shown in Chapter 2. MFI of CD40
increased only in LPS groups but not in Aβ42O groups. CD206 shows increase in
all oAβ42 groups with no significant difference between doses while increase less
extent in LPS group.
To investigate the possible association between mitochondrial function and
cell function at low dose of oAβ42 treatment, we evaluated microglia phenotypical
changes with microglia phagocytosis function. I also conducted the mechanistic
study based on the phenotypical changes.
Previous literatures (Kettenmann et al., 2011) have described the
morphology

change

accompaning

phenotypical

change

during

microglial

activation. In the typical “resting” stage, microglia cells appear quite different from
macrophage. They send out long branching processes to survey the surrounding
environment. Once they detect any signal as a threat to the homeostasis, they are
triggered into transition to activated states with an amoeboid shape to be able to
phagocytose cell debris, lipids and apoptotic cells.
We carried out immunofluorescent imaging to observe cellular morphology
change under different dose of oAβ. Also mitochondria were stained
simultaneously in order to observe any mitochondrial localization change. C8-B4
cells were treated with oAβ and LPS for 24h and stained with Calcein-AM (Green),
DAPI (Blue) and Mito-tracker Red (Red).
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a) Control

c) oAβ 16pM

b) oAβ 3.2pM

d) oAβ 80pM
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e) oAβ 400pM

f) oAβ 2nM

g) oAβ 10nM

h) oAβ 50nM

i) oAβ 250nM
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Fig 3.4 Immunofluorescent imaging bottom left) and Merge (bottom right).of C8-B4 cell after 24h treatment
at various doses of oAβ: a) vehicle control, b) 3.2pM, c) 16pM, d) 80pM, e) 400pM, f) 2nM, g) 10nM, h)
50nM, i) 250nM. In each graph, cells were stained with DAPI (Blue, top left), Calcein-AM (Green, top
right), Mito Tracker Red (Red,
Confocal imaging (Fig 3.4) did not show significant morphological change,
nor show a relationship between mitochondria size and location at any oAβ
concentration (3.2pM to 250nM).

To further specify phenotypical changes at a molecular level, I performed
rtPCR assay using multiple M1 (iNOS, IL-1β, CCL-2, TNF-α) and M2 (Arg1, IL-10,
YM1/2, TNF-α) markers. Data were obtained by calculating ΔΔCT value, ΔΔCT =
ΔCT1 (treated) – ΔCT2 (control). Normalized target gene expression level = 2 ΔΔCT.
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Fig 3.5 Relative mRNA expression level (normalized by L27 housekeeping gene) detected by rtPCR assay.
Microglial classical activation markers (M1, Left panel) and alternative activation markers (M2, right
panel) expression in C8-B4 cells after 24h treatment. Lipopolysaccharide (LPS) and IL-4/IL-10 combo
are M1, M2 positive controls accordingly.
Fig 3.5 show rtPCR results of multiple M1 and M2 marker gene expression,
suggested oAβ across the dosage used from pM to uM does not induce a specific
M1 and M2 gene regulation change. The positive control in each group (LPS and
56

IL-4/10) shown that the markers chosen for each phenotype works fine with the
temperature and cycle determined in our experiment settings. We notice that LPS
also induce some M2 activation (YM1/2) which was also observed in our CD206
flow cytometry assay. Some marker, such as TGF-β, did not respond to IL4/10
combination positive control, demonstrated that certain stimuli initiate specific
spectrum of regulatory marker. These data suggest that there is not a clear cut of
the M1 and M2 marker.

To test whether phagocytosis is influenced by the mitochondrial respiration
change under oAβ treatment, we performed a phagocytosis assay using
fluorescent beads to measure the ability of the general engulfment of microglia
cells, the cells were cultured overnight and treated with a variety dose of oAβ and
LPS as a positive control for 24h. One hour before the end of treatment, cells were
incubated with fluorescent (Nile red) microsphere at 37 °C, with their
corresponding baseline group at 4 °C. It is considered that 4°C is low enough to
force cell into a hibernate state that prevent any phagocytosis activity, thus can
provide a clean background of baseline.
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Fig 3.6 Fluorescent Confocal Imaging of microglia cell C8-B4 phagocytosis assay. Nile Red microsphere
nitrile beads (Red, d=1uM, Lifetechnology), Phalloidin (Green), DAPI (Blue)
Fig 3.6 show a representative picture of the phagocytosis of microglia cells.
The cell morphology is stained by the actin binding Phalloidin in green. The red
microsphere is clearly located either inside the cell (phagocytosis) or bond at the
surface of the cellular membrane.
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C8-B4 Phagocytosis Assay

Vehicle
oAβ 3.2pM

Cell Count

oAβ 16pM
oAβ 10nM
oAβ 50nM

C8-B4 Phagocytosis
Assay
LPS
10ng/ml
Non-stain negative control

Fluorescent Beads (Nile Red)

Fig 3.7 Histogram of Flow Cytometry phagocytosis assay using Nile-red fluorescent microsphere (d=1um).
Mean Fluorescence Intensity (MFI) of the positive peaks show a significant increase of MFI only in LPS
treated group by 2 folds. All oAβ treated groups show little increase compared to vehicle group. Although it
seems to be tread of increase, there is no significant difference under statistical analysis. (Statistical analysis
was done by One-way ANOVA and Dunnett’s post hoc analysis. *** p<0.0005)
Flow cytometry assay using the fluorescent beads and C8-B4 cells provides
better quantification of the extent of phagocytosis in microglia cells. In the
histogram graph, the peaks on the right half of the graphs represent the single,
double, triple and 4+ beads engulfed into the microsphere, the mean fluorescent
intensity increases as the peak shift to right. Fig 3.7 suggested that the oAβ didn’t
induce phagocytosis although there is a small trend of increase in the MFI, this
was not significant. LPS induced 2-fold change of MFI and served a good positive
control.
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Based on the experiment results shown above, we answered the question
that although oAβ induced M2-like microglia activation, it does not inducing
phagocytosis. Thus the energy increase by oAβ treatment may not contribute to
any clearing of oAβ through phagocytosis, suggesting there might be other
clearing mechanism associated with oAβ stimuli or other cellular activity going on
without cellular morphology change.

3.4 Discussion
In this project we answered the question of whether a M2-like activation
induced by low dose oAβ is correlated with phagocytosis activity which assumed to
be energy demanding. The answer by flow cytometry assay suggested no
phagocytosis occurred at the dose of oAβ tested. NFkB translocations usually
happen upon activation, and believed to be a more classical pathway of activation.
In our project, this activation assay— NFkB translocation was not utilized suggest
that this pathway is not utilized at the low dose oAβ stimuli. This needs to be
further confirmed.

The activation marker staining methods worked well as we expected
although M2 marker was not increase strongly. This may due to the very low dose
of the stimuli that cause a prolonged mild response. There is a limitation that the
microglia possessed morphology with shorter elongation of the cellular extensions
(mitochondria clumped around nucleus) compared to neuron and astrocytes which
make it hard to distinguish individual mitochondria even with confocal microscope.
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So the task of observation of the relationship of mitochondrial location and
microglia phenotypical change was not achieved.
The similar patterns of microglia activation with mitochondrial respiration
suggest there is a relationship between these mitochondria and activation,
although the activation could not be further specified. Although previous study
(2014 neurobiology of aging) shown that resting microglia react to Aβ42 fibrils but
do not detect oligomers by their morphology change, it is not sufficient to judge
that resting state microglia does not react with oAβ. Since microglia could undergo
some molecular changes that does not reflect from the morphology changes. As
shown in our experiment, the morphology of microglia does not change under pMnM oAβ treatment but the mitochondrial respiration ability and some protein
expression level are regulated under the treatment without cause cellular shape
change.
To further investigate the mechanism underlying the cell specific response
on mitochondria respiration upon low dose oAβ treatment, there are some future
experiments that can be done
To examine the function of microglia scarvenge ability, Scavenger receptor
A–Scara1 (Yu & Ye, 2014) level could be assessed. Scara1 is thought to be
important in soluble oAβ clearance, thus Scara 1 protein expression and gene
regulation could be tested after oAβ42 treatment in C8-B4 cell and primary glia
cells. Scara1 protein level could be determined by western blot, and gene
expression is tested by rtPCR assay. In addition, to determine whether oAβ42
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affects Scara1-related phagocytosis, selective shRNA library could be used to
silence Scara1, then microglia phagocytosis and mitochondrial respiration could be
assessed.
To test mitochondrial health, fission and fusion protein expression are to be
assessed. Due to the morphology limitation, mitochondrial size distribution cannot
be visualized as in neurons, so fusion protein Mitofusin 1 (MFN1), Mitofusin 2
(MFN2) as well as fission protein Dynamin-related protein 1 (Drp1) and its
phosphorylated form p-Drp1 could be tested either by western blot or ELISA using
different kind of cell types.

62

CHAPTER

4:

MITOCHONDRIAL

RESPIRATION

VS.

MICROGLIAL PHAGOCYTOSIS

4.1 Introduction
In Chapter 3 we discussed the relationship of phagocytosis vs the
mitochondrial respiration induced by oAβ treatment. We have shown that microglia
cell could respond to low doses of the soluble form of oAβ, probably in a way to
lower the environmental amyloid-β burden and help maintain the homeostasis.
Since the oAβ induced a M2-like activation and usually M2 activation is considered
to be phagocytosis preferred, it is originally believed that the oAβ induced
mitochondrial respiration increase is associated with phagocytosis activity which
may demand higher energy supplement with cellular movement and shape
reformation. However the phagocytosis assay demonstrated that there was no
phagocytosis at the time of respiration increase suggests the activation is not
involving phagocytosis. Thus oAβ appears to not induce an amyloid clearing
mechanism through phagocytosis.

Although

during

phagocytosis

cell

undergoes

more

microfilament

movement, membrane folding, vesicle forming, construction change, fusing and
digestion, it is still unclear whether the phagocytosis activity is more energy
consuming or not? If so, what will be the major energy supply pathway in microglia
under phagocytosis to provide the necessary fuel enough for a series of
phagocytic activities?
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In this chapter, we investigated the relationship of mitochondrial respiration
and other energy supply pathway vs. microglia phagocytosis activities.
4.2 Material and Method

Cell culture
C8-B4 (ATCC) cells were grown in DMEM containing 10% fetal bovine
serum and 100units/ml-100μg/ml Penicillin-Streptomycin in 5% CO2 at 37°C.

Phagocytosis assay
To better quantify the extent of phagocytosis in given number of cells,
microglia were subjected to flow cytometry analysis. Treat C8-B4 cell with LPS and
Rotenone for 24 hours. One hour before the end of the treatments, samples were
incubated with fluorescent microsphere. The phagocytosis is proportional to the
incubation time with fluorescent beads until it reaches a plateau at maximal
amount that each microglia cell can handle. Mean fluorescent Intensities were
measured using Fortessa Flow Cytometer, and analyzed by FCS express
software.

Cell Viability assay
Cell viability was assessed using Calcein-AM (Calcein acetoxymethyl)
Assay. Cells were washed with PBS and incubated with 1μM Calcein-AM
fluorescent probes (Life Technologies) in the dark for 30 min. Live cells produce
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green fluorescence by active intracellular esterase which cleaves the Calcein AM
dye. Viability was measured in relative fluorescent units (RFU), and expressed as
percentage of vehicle-treated control values.

Mito Stress and Glycolysis parameter
The mitochondrial respiration function and glycolysis is measured by
analyzing the rate of oxygen and pH change in the microenvironment using
Seahorse extracellular flux analyzer as described in Chapter 2.

4.3 Results
To investigate whether mitochondrial respiration is the main source of the
phagocytosis activity, we apply LPS treatment as the positive control of
phagocytosis. At the same time, we apply rotenone, the specific inhibitor of
mitochondrial respiration electron transport chain complex I enzyme to shut down
most of the oxidative phosphorylation in mitochondria. To correlate the energy
supply resources, we performed mitochondrial respiration evaluation and
glycolysis assay simultaneously.
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Fig 4.1 Mean Fluorescent Intensity calculated from flow cytometry phagocytosis assay. C8-B4
cells treated with Rotenone (5uM, 10uM, 20uM) and LPS 10ng/ml for 24h. (Statistical analysis
was done by One-way ANOVA and Dunnett’s post hoc analysis. * p<0.05, ** p<0.005, *** p<0.0005)
Fig 4.1 shown a dose-dependent decrease in rotenone treated group of C8B4 cells, suggested that rotenone induced a decrease in phagocytic activities.
Since rotenone is mitochondrial inner membrane electron transport chain complex
I inhibitor, it hinted that phagocytosis in C8-B4 cells may largely dependent on
oxidative phosphorylation happened in mitochondria. LPS is known to induce
phagocytosis thus serve as a positive control.

As a gold standard to induce phagocytosis, LPS is used as a phagocytosis
inducer by working through the surface toll-like-receptor mediated signaling
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cascade. Thus to investigate the relationship of phagocytosis vs energy supply, we
use different dose of LPS to test both Mito Stress parameters and glycolysis ability.
Fig 4.2 shown LPS doesn’t affect the basal and ATP related mitochondrial
respiration but decrease the maximal and spare respiration in mitochondria.
Surprisingly, the results are opposite to what we hypothesized that phagocytosis
requires much energy which shifts the cellular energy supply gear into a more
oxidative phosphorylation favored pathway. The results indicate that during
phagocytosis, the machinery of mitochondria to generate spare ATP, which
directly associated with the ability of maximal respiration, is decreased. With the
basal and ATP associated respiration were not affected LPS did decrease the
mitochondria’s ability to produce more ATP, when cells encounter an energy crisis.
Rotenone inhibits all parameters of mitochondrial respiration to zero.
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Fig 4.2 mitochondrial stress parameters were measured as oxygen consumption rates (OCR) in C8B4 mouse microglia cell line (Statistic analysis was done by One-way ANOVA and Dunnett’s post hoc
analysis. * p<0.05, ** p<0.005, *** p<0.0005) There were significant differences in maximal and spare
respiration parameters treated with LPS in C8-B4 cell line. The reduction of basal and ATP production
OCR in 100ug/ml group is presumably caused by cytotoxicity. Rotenone 5uM is enough to inhibit the OCR
to zero while LPS combination treatment doesn’t reverse or remedy the rotenone inhibitory effect.

When mitochondrial function is inhibited, cells utilize other energy source
and/or reduce the energy expenditure. Glycolysis is one of the major energy
generation reactions besides oxidative phosphorylation, and usually it change
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reciprocally with mitochondrial respiration. Compared to mitochondrial ox-phos
respiration, glycolysis generate much less energy per glucose, but the whole
reaction provide the substrate for mitochondria, and other reaction material.

Fig 4.3 Glycolysis parameters calculated by ECAR from Glycolysis Assay in C8-B4 cells. Low
dose LPS treatment seems to induce a little increase in all three glysolysis parameters. Rotenone with or
without LPS combination inhibit all glycolysis to a very low level. (Oneway-ANOVA Tukey’s Post hoc
analysis)

Fig 4.3 shows the glycolysis parameters measured in LPS treated C8-B4
cells suggested that energy compensation may be involved. The LPS
phagocytosis probably depends on glycolysis provided energy rather than
mitochondria provided energy. Interestingly, rotenone not only inhibits the
mitochondria oxphos respiration, it also inhibit the glycolysis. In this case, rotenone
reduced both energy reaction pathway to a very low level, but C8-B4 survived over
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24h suggested that either the microglia cell line could utilize other energy source to
replenish the shortage of energy supply, or it restricted its energy expenditure
accordingly to a much lower level by shutting down some features of cellular
function in order to survive under the extreme condition. C8-B4 cells survival
tested by PI and Calcein-AM assay suggested that C8-B4 cell well survived after
24h in under both 5uM and 10uM rotenone treatment.

PI

Calcein-AM

Fig 4.4 Viability of C8-B4 cells treated with rotenone 5uM and 10uM for 24hs PI and CalceinAM assay. No significant difference in rotenone treated group compared to vehicle control.
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To document that there is a energy supply needed for the phagocytosis,
rotenone was co-administered with various dose of LPS to test whether its
inhibition effects on oxphos and glycolysis also exhibit in phagocytosis.

Fig 4.5 Mean Fluorescent Intensity calculated from flow cytometry phagocytosis assay. C8-B4 cells
treated with LPS (0.1, 1, 10, 100, 1000ng/ml) with or without Rotenone 10uM for 24h. (Two-wayANOVA, * stands for the comparison within same treatment group. # stands for the comparison in
different treatment group under same LPS regimen.)

Fig 4.5 shows that the rotenone inhibits basal phagocytosis compared to
vehicle group, which duplicated the result in Fig 4.1. LPS has been shown to
induce a dose-dependent increase of phagocytosis in C8-B4 cell after 24h
treatment. Compare to Fig 4.3, the increase of phagocytosis is not direct
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proportional to the increase of glycolysis change suggest that the phagocytosis is
not solely dependent on glycolysis for energy supply. Since rotenone inhibits both
oxphos and glycolysis in the C8-B4 cells, the rotenone treated C8-B4 has a
reduced ability to phagocytose. The co-treated group induced an increase
compared to 10uM rotenone group suggested that LPS treatment could reverse or
partially remedy the rotenone inhibition on glycolysis. LPS may lead to initiate
glycolysis reaction which avoiding the rotenone inhibition on glycolysis in order to
generate ATP needed in microglial phagocytosis.

4.4 Discussion
The energy expenditure in neuron has been extensively studied, as
neurons are high energy demanding, high glucose consuming cells in the brain. In
contrast, microglia, due to their multi-function, multi-phenotype, and dynamic
states, are not well characterized for their energy demand and mitochondria
function. Considering the digesting process in the later phases of phagocytosis, it
make sense that glycolysis is preferred, since glycolysis help generate more acidic
molecule in cytosol when low pH environment is needed to break down and digest
engulfed material. To better and more efficiently serve its job, lysosome ideal pH
environment is around 4.5, a relatively acidic fluidity to better provide a working
condition for hydrolytic enzymes which breaking down virtually all kinds of
bimolecular targets. Glycolysis is favored over mito-respiration in energenesis
during immunogenic induced activation of microglia cell line C8B4 due to
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preparation of acidity from anaerobic respiration for phagocytic lysosome, only
when critical survival energy supply is fulfilled.
Others results shown that rotenone could induce microglia cell (BV-2)
directly (Gao, Chen, Hu, & Wang, 2013). Rotenone IC50 varies from 0.1 nM to 100
nM (W. S. Choi, Kruse, Palmiter, & Xia, 2008), at nanomolar rotenone stimulates
microglia and enhances phagocytic activity without affecting mitochondrial
membrane potential (Emmrich, Hornik, Neher, & Brown, 2013) (Chang et al.,
2011). It further supports the hypothesis that the fluctuation of mitochondrial
energy production would affect microglial activation.
Microglia can still maintain similar level of basal mitochondrial oxphos to
cope with basal activity needs other than phagocytosis. The phagocytosis may
depend more on glycolysis not for the ATP generated.
One pitfall in our experiment is the inhibition of oxphos by rotenone is not
complete. Since Complex II, III are not inhibited, there is still other possible ways to
provide electron transport to generate a proton gradient, although the contribution
through this route is very limited. In the future, to fully inhibit the oxphos reaction,
1uM Antimycin A (a complex III inhibitor) can be co-treated with rotenone to fully
inhibit the whole ETC reaction.
Another possible experiment is to test the cytosol pH change after LPS
treatment with an increased phagocytosis activity to test the hypothesis that the
glycolysis is favored because of its acidic end production is beneficial to digest
phagocytosed particles. The pH change may be subtle and transient since the
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proton may be segmented and utilized in other organelles very quickly without
fluctuating whole cell pH too much for a long time.
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CHAPTER 5: DISCUSSION

Microglia, the immune cell in the brain, protects neuron by digesting Aβ
plaque in Alzheimer’s disease (AD) (C. Y. Lee & Landreth, 2010).Upon activation,
microglia cells could present pro- or anti-inflammatory phenotypes (Varnum &
Ikezu, 2012). Along the disease progress, microglia shifts its anti-inflammatory to
pro-inflammatory phenotype, which may results in inefficiently Aβ clearance and
inflammatory burden.
Since gliosis is considered to be another main factor contributes to AD,
manipulating microglia activation is believed to be both beneficial for plaque
reducing and for reducing inflammatory pressure. However, the role of microglia in
brain is not yet fully understood, while some researchers argue the necessity of
microglia in the neurodegenerative disease progression. BY utilizing ColonyStimulating Factor 1 receptor (CSF1R) inhibitor, microglia cells could be largely
eliminated in healthy WT young mice (a microglia depleted mouse model). Dr.
Green and his co-workers found out that the microglia depleted mice are healthy,
fully viable and have no obvious defects. What’s more, they don’t appear behavior
impairments nor cognition & motor function deficits (Elmore et al., 2014). In spite of
all the possible hypothesized microglial contributions to neuronal degenerative
disease, the minimal influence of microglia depletion in healthy brain suggests the
complex role microglia plays in the brain system which needs to be addressed and
further studied.
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Many groups recently use in vitro and in vivo models to test the different
roles of microglia activation phenotypes, as well as the feasibility of microglia
activation inducing reagents as possible therapeutic methods. But lack of efficient
and accurate way to determine the activation status make results analysis difficult
to interpret. But overall it is possible that understanding microglia activation will
play an important role in eliminating or at least postponing the occurrence of AD.
Alzheimer's disease (AD) is a neurodegenerative disease which is
irreversible and progress overtime. AD is the most common form of dementia,
causing memory loss and cognition decline as well as changes in other brain
functions. AD is the 6th leading death in the United State, in 2015 together with
other type of dementias; it cost $226 billion to American society. By 2050, these
costs could rise as high as $1.1 trillion (http://www.alz.org/facts). Until now the
etiology of the disease is still not understood, and no treatment can stop the
disease progressing.
The greatest risk factor known of AD is age, but other risk factors include
family history, genetic background, head trauma, heart disease, high blood
pressure, diabetes and high cholesterol. There are two main neuropathological hall
marks of AD pathology, extracellular fibrillar β-amyloid (Aβ) deposition and
intracellular hyperphosphorylated tau neurofibrillary tangles (NFT)(Querfurth &
LaFerla, 2010). There is still debate about the role of the two hall marks in the AD
pathological molecular mechanisms. But it is believed that the aggregation of Aβ,
either by overproduction of Aβ or the failure of clearance of the Aβ, cause
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neurotoxicity which further cause synaptic dysfunction, neuronal cell death,
cognition impairment.
While the Amyloid Hypothesis is supported, there are still several questions
that cannot be answered. If the Aβ is the causative factor, why removing Aβ
fabrillar tangle does not rescue the progression of AD (Salloway et al., 2009) ? And
why Aβ is also found in healthy brains, never develop dementia (Aizenstein et al.,
2008)? Other factors, such as gliosis—inflammation of glial cells, is considered to
be an important contributor to AD pathoetiology. Extracellular Aβ can induce
microglia activation by binding to certain receptors such as receptor for advanced
glycation end products (RAGE) and CD36, resulting in activated microglia cells
and release of cytokine, chemokines, ROS release. The released substance could
be pro- or anti-inflammatory, which could be detrimental or beneficial depending on
individual condition. Fibrillar Aβ can interact with CD14; TLR2; TLR4, thus trigger
inflammatory signaling pathway. It is reasonable that phagocytosis of Aβ by
microglia cells decrease during the disease progression. Thus at the late stage of
AD although Aβ levels are still high, the ability to clear Aβ reach at capacity or
even reduced (Hickman, Allison, & El Khoury, 2008; Sastre, Richardson,
Gentleman, & Brooks, 2011).
Microglia cells are innate immune cells in the brain and compose 1/10th of
the cell population of CNS. They are important in first-line defense against
pathogens, clearance of damaged cell and debris, monitoring neural environment,
repair, and also critical in brain development. They share many common receptors
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with peripheral immune cells, such as major histocompatibility complex (MHC),
and cluster of differentiation (CD) receptors.
Upon activation, microglia display 2 major activation phenotypes in
response to the cytokines, chemokine, and innate immune surface receptors
presented in the environment. Between different activation types, microglia cells
bind with different profiles of specific ligands and express different markers and
have different effects on neuronal functions such as synaptic plasticity,
neurogenesis, etc.
First activation phenotype is classical activation, which is characterized by
release of pro-inflammatory factors such as matrix metalloproteinase (Jourquin et
al., 2003), interleukins, monocyte chemotactic protein-1 (S. H. Kim, Han, Azam,
Yoon, & Dinarello, 2005), tumor necrosis factor (Combs, Karlo, Kao, & Landreth,
2001) and interferon-gamma (Ponomarev, Shriver, & Dittel, 2006). The second
activation phenotype is alternative activation with two sub category, antiinflammatory and deactivation phenotypes. Under anti-inflammatory phenotype,
microglia cells enhance neurogenesis (Carpentier & Palmer, 2009), increase
phagocytosis and synaptic plasticity (Nolan et al., 2005), and improve spatial
learning (Kiyota et al., 2010). Under deactivation phenotype, microglia cells
secrete IL-10 and TGF-β and enhance neurogenesis and wound healing.
Activated microglia in close vicinity to amyloid plaques can internalize and
degrade Aβ in different manners. For the soluble Aβ form, microglia respond with
pinocytosis and LDL receptor-related proteins (LRPs) pathway. For fibrillar plaque,
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microglia cells bind through its surface receptors to initiate intracellular signaling
pathway that either stimulate phagocytosis or cytokine release.
Similar to peripheral immune cells, microglia cells also undergo an agerelated decline of immune functions. Compare to the normal brain, AD brain shows
exacerbated impairment like dystrophic microglia with shortened telomere
(Flanary, Sammons, Nguyen, Walker, & Streit, 2007) which may be caused by Aβ.
Also microglia morphology is changed in aged mice by forming few bifurcation, few
branches and reduced total branch length (Baron, Babcock, Nemirovsky, Finsen,
& Monsonego, 2014).
Although the mechanism of Aβ induced microglia activation is still not fully
understood, much researches studied the possible surface molecules which
respond to Aβ stimuli associated with inflammatory response. Table 5.1 has listed
the reacting surface molecules which bind direct to Aβ stimulation (Left), and the
inflammatory molecules of microglial cells in response to Aβ stimulation secreted
(Right).
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Table. 5.1
Microglia

Surface

receptor

to

Aβ Inflammatory mediator released upon Aβ

stimulation

stimulation

Integrin (Sonkar, Kulkarni, & Dash, 2014)

IL1-β (Parajuli et al., 2013)

CD36(Sheedy et al., 2013)

TNFα (Yang, Shang, Zhao, Fang, &

SR-A (Schmidt, Yan, Yan, & Stern, 2001)

Chen, 2013)

CD47 (Floden & Combs, 2011)

NO

TLR2, TLR4

CXCL8(IL-8) (Franciosi et al., 2005)

CD14 (Reed-Geaghan, Savage, Hise, & MCP-1(CCL2) (Cho et al., 2013)
Landreth, 2009)

CX3CR1 (S. Lee et al., 2010)

P2X7 (Sanz et al., 2009)

MIP-1α(CCL3) (Fiala et al., 1998)

RAGE(Fang et al., 2010)

CXCL10 (Lyons, Murphy, Clarke, &
Lynch, 2011)
Prostaglandins

(Bate,

Kempster,

&

Williams, 2006; Nagano, Kimura, &
Takemura, 2010)
Table 5.1 Inflammatory mediators released by microglia corresponding to microglial surface receptors and
their binding ligands.
While inflammation hypothesis draw a lot of attention in the field, many
approaches have been applied to control the activation of microglia in order to
either clear Aβ or further reduce the inflammatory level (D. C. Lee et al., 2013).
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Microglia activation could be manipulated by TLR activation such as
administration of LPS. The results are opposites based on different experiments
settings, some observed a less profound amyloid deposition (DiCarlo, Wilcock,
Henderson, Gordon, & Morgan, 2001), while others observe a reduced amyloid
clearance, which probably due to a mutated TLR4 background in APP mice which
lead to reduced response of CCL3, CCL4 and IL-1 (Song et al., 2011). Based on
the opposite results it is hard to determine the role of microglia activation. But in
general study show that acute LPS or TLR4 KO causes microglia activation,
promoting amyloid clearance, while chronic LPS or CD14 KO causes reduced
microglia activation and increased Aβ deposition. Lack of a standard microglia
activation evaluation increases the difficulty in judging the different activation
states and the benefit outcomes for Aβ reduction. While LPS treatment induces
microglia activation, LPS fails to reduce NFTs in Tg4510 mouse. In vitro model
show that Interleukin-1 induces phosphorylated tau accumulation through
microglia.
On the other hand, anti-inflammatory drugs have been applied to test the
Alzheimer’s Inflammation hypothesis. Non-steroidal Ibuprofen and PPAR-γ agonist
pioglitazone have been applied to Tg2576 APP mice. Ibuprofen treatment reduced
Aβ deposition and phosphotyrosine in activated microglia, reduced IL-1β and
astrocyte activation marker GFAP (Lim et al., 2000). Pioglitazone as well as
rosiglitazone also reduce the amyloid level and microglia activation. Some other
drugs such as COX-2 selective drug, celecoxib show similar results (J. K. Choi et
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al., 2010). Curcumin, an extract from turmeric, has been tested in APP mice and
Aβ infusion model. Interestingly, it suppress the amyloid and IL-2 while increase
the activation of microglia surrounding Aβ plaque deposits (Yan et al., 2001). Due
to the lack of fully characterization of the activated microglia phenotype induced by
curcumin, it is hard to determine whether curcumin could mediate microglia
activation only lead to Aβ clearance without generating excess pro-inflammatory
cytokines.
Prospecting the immunotherapy in AD treatment, the effect of antibodies
against Aβ on the microglia activation has been tested in APP mice (Morgan,
2009; Schenk et al., 1999). Depending on the antibody administration regimen and
experiment design difference, the microglia activation marker expressions are not
consistent.
Neurodegenerative

diseases

are

characterized

not

only

by

activation of microglia but also by the mitochondrial dysfunction. Mitochondrial
dysfunction in microglial cells has been observed to inhibit part of M2 activation
which is usually considered to be associated with cellular self-healing and antiinflammatory responses (Ferger et al., 2010). When microglia get activated by
bacterial lipopolysaccharide and interferon-gamma, the microglial mitochondrial
morphology changed to more elongated shapes with an

increase in the

abnormalities such as circular cristae or ring- and U-shaped membranes (Banati et
al., 2004). Researchers recently found out that mitochondrial dynamics are closely
associated to production of pro-inflammatory mediators upon LPS stimulated
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microglial cell lines. Mitochondria fission activity was observed up-regulated
following LPS stimulation and mitochondria localization with mitochondria fission
protein Dynamin-related protein 1 (Drp1) is also increased through a NF-kB and
Mitogen-Activated Protein Kinase (MAPK) mediated pathways (Park et al., 2013).
Inflammation caused by microglia activation is considered an important
component of AD neuropathology. Due to the complex role of microglia in CNS,
and the even more complex status after activation, much research have led to very
opposite conclusion regarding the function of microglia in AD. Using various AD
model both in vivo and in vitro, microglia cells are associated with both Aβ
clearance and inflammation. The effects of treatment or manipulations on microglia
activation phenotypes are limited at present. But recent studies show that the antiinflammatory methods show a positive effect in AD model. Also manipulation of
specific microglia activation has a potential for possible treatment of AD and needs
to be further investigated.
While experiments on Aβ plaque clearance show positive results, there is
lack of cognitive behavior tests that support a positive clinical outcome. If the
differentiations of microglia activation phenotypes positively correlate with the AD
progression, it may enable us new methods to diagnosis and intervention.
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